Novo Nordisk is a global healthcare company specializing in diabetes care, obesity treatment, and hormone replacement therapy. Its core products include insulin, GLP-1 receptor agonists, and growth hormone therapies. The company operates primarily in diabetes care and biopharmaceuticals, with major revenue sources stemming from its diabetes and obesity segments. Novo Nordisk is recognized for its innovative drug development and strong market presence in these therapeutic areas.
The investment profile of Novo Nordisk is more aligned with growth investors, given its focus on innovative therapies and expanding market opportunities. The company also offers a dividend yield, appealing to those seeking income. Its stable revenue growth and moderate volatility suggest a balanced approach may be suitable for investors with varying risk appetites.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-11 05:23 | Sell | Hold | Strong fundamentals, but recent negative momentum concerns. |
| 2026-06-09 02:47 | Hold | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-06-01 02:46 | Buy | Hold | Strong fundamentals and positive momentum support growth potential. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-02-05 12:38 | BMO Capital | Target Lowered | 57 → 45 | 47.19 |
| 2026-01-26 14:36 | BMO Capital | Target Raised | — → 57 | 63.8 |
| 2025-12-10 11:16 | HSBC | Target Raised | 47 → 54 | 46.36 |
